FFA
ATHE

Farther Finance Advisors’s Alterity Therapeutics ATHE Stock Holding History

Farther Finance Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205 Buy
39
+17
+77% +$74 ﹤0.01% 5715
2026
Q1 		$80 Hold
22
– – ﹤0.01% 5535
2025
Q4 		$68 Hold
22
– – ﹤0.01% 5329
2025
Q3 		$83 Buy
+22
New +$106 ﹤0.01% 4835

Other funds holding ATHE

GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Farther Finance Advisors's ATHE Position: Q2 2026 in Review

Farther Finance Advisors increased its Alterity Therapeutics (ATHE) stake by 77% in Q2 2026, buying an estimated $74 and bringing the position to 39 shares worth $205. The position accounts for ﹤0.01% of the portfolio, ranked #5715.

Farther Finance Advisors first reported a position in ATHE in Q3 2025 and has held it in 4 quarters since. 5 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • Farther Finance Advisors held 39 shares of Alterity Therapeutics worth $205 as of Q2 2026.
  • Farther Finance Advisors bought 17 Alterity Therapeutics shares in Q2 2026, an estimated $74.
  • Alterity Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5715 holding.
  • Farther Finance Advisors first reported a position in Alterity Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 5 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.